New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 20, 2014
11:56 EDTFLMLFDA change on neostigmines could be significant for Flamel, says Summer Street
Summer Street notes that the FDA has changed its drug shortage website and now lists Flamel Technologies' Bloxiverz as the "first and only" approved neostigmine, which the firm thinks may mean that the FDA could be taking action to remove unapproved neostigmines from Fresenius or West-Ward Pharma. Summer Street thinks this change could be a "hugely significant" milestone for Flamel and its Eclat strategy and reiterates its Buy rating and $24.75 price target on the share.
News For FLML From The Last 14 Days
Check below for free stories on FLML the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 16, 2014
08:52 EDTFLMLFlamel Technologies has multiple catalysts in second half, says Summer Street
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use